Researchers used a blood protein wash to render brain tissue transparent down to 700 µm, witnessing live-firing activity without killing a single neuron.
Get the latest international news and world events from around the world.
Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial
A personalized vaccine to treat glioblastoma, a fast-growing and incurable brain cancer that affects four in 100,000 people in the U.S., is safe and elicits robust and broad immune responses that appears to increase recurrence-free survival in a subset of patients after surgery, according to an early-stage clinical trial co-led by researchers at Washington University School of Medicine in St. Louis.
In patients with an especially aggressive form of glioblastoma, the vaccine caused no serious side effects and prolonged patients’ overall survival compared to historical outcomes after standard-of-care surgery and chemo-radiotherapy. One long-term survivor remains recurrence-free nearly five years later.
The results of the phase 1 trial, conducted at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, were published May 12 in Nature Cancer. The study was led jointly by Mass General Brigham and Geneos Therapeutics, a Philadelphia-based biotechnology company.
“We are extremely encouraged by these results,” said Tanner M. Johanns, MD, PhD, lead author of the study and an assistant professor in the Division of Oncology in the John T. Milliken Department of Medicine at WashU Medicine. “This kind of vaccine is a first for glioblastoma, and it is exciting to think how we can leverage this individualized therapeutic DNA cancer vaccine platform to make a positive impact on the lives of patients who are fighting this disease. Additionally, combination therapies leveraging this personalized platform are currently being investigated at WashU to test if outcomes may be improved further.”
Abstract: Nature Cancer
Johanns and colleagues report the results (including safety, efficacy and immunogenicity) of a phase 1 clinical trial of a DNA-based personalized therapeutic cancer vaccine administered following surgical resection and radiation in patients with MGMT unmethylated glioblastoma.
3D-printed ceramic implants that mimic human bone could enable patient-matched repair
Researchers at Tampere University, Finland, have developed a groundbreaking 3D-printed ceramic implant material that closely mimics real human bone. The findings advance the development of personalized bone regeneration and may lead to more effective and accessible treatments for bone defects.
The research article, titled “Biomimetic bone calcium phosphate-based scaffolds fabricated via ceramic vat photopolymerization: Effect of porosity, sintering temperature, mineralogical phases and trace elements on the osteogenic potential,” was published in Materials Today Bio.
Bone grafting is the second most common tissue transplantation procedure worldwide, with more than 2 million operations performed annually. Current treatments often rely on bone taken from the patient or a donor, approaches that are limited in availability and may involve additional surgery, lengthy recovery times and complications. As populations age, the need for safer and more effective alternatives is growing rapidly.
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion
In this study, we identify an unexpected and previously unrecognized role for PI3Kδ in promoting stromal fibrosis in PDAC, expanding its known function beyond immune regulation. Through mechanistic and preclinical studies, we show that PI3Kδ controls the biosynthesis of LPA in cancer cells and stromal fibroblasts, establishing an immunometabolic axis that sustains both fibrosis and immune evasion in PDAC.
Strikingly, PI3Kδ inhibition alone was sufficient to suppress tumor growth, reduce fibrosis, restore antitumor immune responses, and prolong survival across multiple PDAC models. Dual inhibition of PI3Kδ and ATX produced additive effects on stromal remodeling and immune activation, significantly enhancing responsiveness to chemotherapy and PD-1 blockade. These findings position PI3Kδ as a central regulator of the PDAC tumor microenvironment and highlight its therapeutic targeting, alone or in combination, as a promising strategy to treat PDAC.
Cell therapy offers ‘real hope’ for people living with cirrhosis
A pioneering treatment which could slow or reverse liver failure and offer a potential alternative to liver transplants has shown positive results in a medical trial.
70% of end-stage liver disease patients who were treated with macrophage cell therapy in the MATCH trial did not need a liver transplant after four years, compared with just 40% who didn’t receive the treatment.
The cell therapy takes immune cells from the patients’ blood and turns them into mature macrophages – a white blood cell – which is then re-injected back into the patient. The macrophages travel to the liver, where they break down scar tissue, reduce inflammation, and encourage the growth of healthy liver cells.
